masterThesis
Caracterização estrutural e potencial antimicrobiano, antiparasitário e antiproliferativo de novos peptídeos análogos da stigmurina
Fecha
2019-03-25Registro en:
CARMO, Bruno Amorim do. Caracterização estrutural e potencial antimicrobiano, antiparasitário e antiproliferativo de novos peptídeos análogos da stigmurina. 2019. 99f. Dissertação (Mestrado em Ciências Farmacêuticas) - Centro de Ciências da Saúde, Universidade Federal do Rio Grande do Norte, Natal, 2019.
Autor
Carmo, Bruno Amorim do
Resumen
In the venom of scorpions, it is possible to find a rich source of biologically active
components with high potential for therapeutic and biotechnological application, and can
be used as prototypes to obtain new drugs. The objective of this study was to characterize
the structural conformation, evaluate the antimicrobial, antiparasitic, antiproliferative
activities and demonstrate the possible mechanism of action associated to these activities,
using the molecular dynamics of two new analog peptides of the Stigmurina scorpion
peptide, named StigA25 and StigA31. The amino acid substitutions in the native sequence
for lysine residues resulted in peptides with higher positive net charge and hydrophobic
moment, with an increase in the theoretical helical content. In the analysis by circular
dichroism, the analog peptides presented the ability to modify their structural conformation
depending on the medium in which they are found, presenting thermal stability at a wide
pH and temperature variation, with similar results for the native peptide. StigA25 and
StigA31 demonstrate a broad spectrum of antimicrobial and antiparasitic T. cruzi activity
in vitro with an effect superior to the native peptide and reference antibiotics, with a reduced
hemolytic effect at concentrations that present biological activity and antiproliferative
activity in HeLa cells. Therefore, this study demonstrates the therapeutic potential of such
analog peptides and the promising effect of peptide engineering for the potential
development of novel therapeutic agents.